Loading
Evolus, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 18 Aug 2025.
Evolus, Inc.: what insiders have been doing
Evolus, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Evolus, Inc. logged 15 filings by 8 insiders.
There is no open-market purchase to report; the filings show 5 sales worth €967k by 2 insiders. At €820k, the sale published on 4 September 2026 by Moatazedi David is the largest of the period (0.18% of market cap).
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 15 filings here. The full history, which starts in 2021, counts 15 purchases against 61 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 297.2 m USD and net income at -51.6 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
141
Thresholds
n/a
Buy Volume
€4M
15 ops. · all time
Sell Volume
€44M
61 ops. · all time
Who traded when
BuySaleDavid Moatazedi8 sales
Rui Avelar5 sales
Sandra Beaver3 sales
Tomoko Yamagishi-Dressler2 sales
Albert G. White III1 buy
Brady Stewart1 buy
+1 other insider
Since the insiders bought
- +20.6%Entry US$7.13 · Close at T+365 US$8.60
- -36.4%Entry US$10.24 · Close at T+365 US$6.51
- -11.5%Entry US$10.33 · Close at T+365 US$9.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Evolus, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$15.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,293 of 24,166 companies
31.0
score / 100
Value15
Quality47
FCF yld-11%
Earn yld-11%
EV/EBITDA·
ROE·
Gross mgn66%
Net mgn-17%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.51
Analyst consensus
5 analystsStrong buy
US$12.00Target US$15.00(+100%)US$20.00
Income statement
RevenueUS$297.2M
Gross profitUS$197.1M66% margin
EBITDA-US$22.5M-8% margin
Net income-US$51.6M-10.8% margin
Valuation
PER (forward)25.7x
Beta1.34
Balance sheet & cash
Market capUS$496M
Total debtUS$155M
Free Cash Flow-US$50.7M
Profitability & ownership
ROA-5.7%
% insiders11.2%
% institutions77.7%
Last declaration on 4 September 2026
Declarations141 total
105,108 shares@ US$9.03850.18% mcap8.7% of flowCommon StockSEC:0001700836-26-000003:0
3,119 shares@ US$4.751.1% of flowCommon StockSEC:0001570562-26-000050:0
13,669 shares@ US$4.75010.6% of flowCommon StockSEC:0001570562-26-000049:0
8,804 shares0Common StockSEC:0001570562-26-000045:0
67,489 shares0Common StockSEC:0001570562-26-000046:0
45,559 shares0Common StockSEC:0001570562-26-000026:0
45,559 shares0Common StockSEC:0001570562-26-000022:0
94,913 shares0Common StockSEC:0001570562-26-000021:0
45,559 shares0Common StockSEC:0001570562-26-000020:0
45,559 shares0Common StockSEC:0001570562-26-000027:0
121,489 shares0Common StockSEC:0001570562-26-000025:0
45,559 shares0Common StockSEC:0001570562-26-000024:0
313,212 shares0Common StockSEC:0001570562-26-000023:0
10,539 shares@ US$7.15070.015% mcap0.7% of flowCommon StockSEC:0001570562-25-000119:0
2,261 shares@ US$7.15070.0032% mcap1.2% of flowCommon StockSEC:0001570562-25-000118:0
104,603 shares0Common StockSEC:0001570562-25-000114:0
5,722 shares@ US$7.510.0086% mcap21.4% of flowCommon StockSEC:0001570562-25-000105:0
30,000 shares@ US$6.8162100.0% of flowCommon StockSEC:0001570562-25-000102:0
Canonical exit: 13 Nov 2025 (T+90)
111,323 shares@ US$10.053110.3% of flowCommon StockSEC:0001570562-25-000089:0
20,000 shares@ US$9.45100.0% of flowCommon StockSEC:0001570562-25-000087:0
Canonical exit: 7 Sept 2025 (T+90)
3,385 shares@ US$9.86612.6% of flowCommon StockSEC:0001570562-25-000081:0
15,787 shares@ US$9.86611.5% of flowCommon StockSEC:0001570562-25-000079:0
6,494 shares@ US$10.0216.3% of flowCommon StockSEC:0001570562-25-000080:0
6,251 shares@ US$12.400.8% of flowCommon StockSEC:0001570562-25-000056:0
103,376 shares@ US$13.25513.4% of flowCommon StockSEC:0001570562-25-000051:0
25 of 141 declarations
About Evolus, Inc.
Evolus, Inc. (NASDAQ: EOLS) is a U.S.-listed aesthetics company traded on the NASDAQ market in the United States (United States). Headquartered in Newport Beach, California, the company focuses on the cash-pay medical aesthetics segment, where patients typically pay out of pocket and providers compete on brand, convenience, clinical performance, and patient engagement. Evolus positions itself as a “performance beauty” company, combining differentiated injectable products with a digital, customer-centric commercial model. ([investors.evolus.com](https://investors.evolus.com/overview/default.aspx))
The company’s foundation rests on Jeuveau® (prabotulinumtoxinA-xvfs), a botulinum toxin type A product approved by the FDA in 2019 for the temporary improvement of moderate to severe glabellar lines. Outside the United States, the same product is marketed as Nuceiva®. Evolus has since expanded beyond neurotoxin into hyaluronic acid fillers with Evolysse®, a next-generation injectable HA gel collection launched in the U.S. in 2025; internationally, that line is branded as Estyme®. These products target core aesthetic use cases such as facial lines, contouring, and volume restoration. ([investors.evolus.com](https://investors.evolus.com/overview/default.aspx))
Read moreShow less
From a competitive standpoint, Evolus operates in a crowded market dominated by large global aesthetics and pharmaceutical players. Its investment case depends on sustained share gains, brand relevance, repeat usage, and the successful rollout of a broader multi-product portfolio. The company highlights its Evolus Rewards™ loyalty platform as a key commercial differentiator, supporting patient retention and physician engagement. Management also states that Jeuveau has reached about 14% U.S. market share, which underscores meaningful traction for a relatively focused player in the neurotoxin category. ([investors.evolus.com](https://investors.evolus.com/overview/default.aspx))
Geographically, Evolus is still anchored in the U.S. but is clearly building an international footprint. Its product portfolio is sold across multiple markets, including the United States, Canada, Europe, and Australia, with further expansion underway. In 2026, the company announced the commercial launch of Estyme injectable HA gels in Europe and outlined plans for additional U.S. and international milestones. This makes Evolus more than a one-product story: it is evolving into a broader aesthetics platform with cross-border growth potential. ([investors.evolus.com](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-First-Quarter-2026-Financial-Results-Company-Delivers-Second-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Reaffirms-Full-Year-Outlook/default.aspx))
Recent operating updates have been constructive. In its first-quarter 2026 results, Evolus reported $73.1 million in revenue, 7% year-over-year growth, and a second consecutive quarter of positive Adjusted EBITDA. Management also reaffirmed full-year 2026 guidance for revenue of $327 million to $337 million and continued to point to margin improvement and operating leverage. For investors, the key takeaway is that Evolus is transitioning from a single-brand growth story toward a more diversified aesthetics franchise, while still facing the execution and competitive risks typical of a consumer-driven, cash-pay healthcare business. ([investors.evolus.com](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-First-Quarter-2026-Financial-Results-Company-Delivers-Second-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Reaffirms-Full-Year-Outlook/default.aspx))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
